Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach

Imipenem/cilastatin/relebactam is a β-lactam/β-lactamase inhibitor that has been recently FDA approved for complicated intra-abdominal and urinary tract infections under the brand name Recarbrio®. It has activity against imipenem non-susceptible Pseudomonas species as well as KPC-producing Enterobac...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghazi, Islam M., El Nekidy, Wasim S., Asay, Regan, Fingmori, Paul, Knarr, Anthony, Awad, Mina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233540/
https://www.ncbi.nlm.nih.gov/pubmed/32421696
http://dx.doi.org/10.1371/journal.pone.0233335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233540/
https://www.ncbi.nlm.nih.gov/pubmed/32421696
http://dx.doi.org/10.1371/journal.pone.0233335

Ejemplares similares